JP2000509961A - 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体 - Google Patents
共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体Info
- Publication number
- JP2000509961A JP2000509961A JP08511066A JP51106696A JP2000509961A JP 2000509961 A JP2000509961 A JP 2000509961A JP 08511066 A JP08511066 A JP 08511066A JP 51106696 A JP51106696 A JP 51106696A JP 2000509961 A JP2000509961 A JP 2000509961A
- Authority
- JP
- Japan
- Prior art keywords
- antibodies
- epidermidis
- antigen
- protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007433 antigens Proteins 0.000 title claims abstract description 145
- 102000036639 antigens Human genes 0.000 title claims abstract description 145
- 239000000427 antigen Substances 0.000 title claims abstract description 144
- 230000003571 opsonizing effect Effects 0.000 title claims description 32
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 120
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 120
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
- 206010041925 Staphylococcal infections Diseases 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000012360 testing method Methods 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 77
- 241000295644 Staphylococcaceae Species 0.000 claims description 55
- 150000004676 glycans Chemical class 0.000 claims description 43
- 229920001282 polysaccharide Polymers 0.000 claims description 43
- 239000005017 polysaccharide Substances 0.000 claims description 43
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 38
- 230000014207 opsonization Effects 0.000 claims description 37
- 229960005486 vaccine Drugs 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 34
- 230000009257 reactivity Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 30
- 230000001717 pathogenic effect Effects 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 24
- 244000005700 microbiome Species 0.000 claims description 24
- 230000001662 opsonic effect Effects 0.000 claims description 24
- 108010052285 Membrane Proteins Proteins 0.000 claims description 19
- 230000000844 anti-bacterial effect Effects 0.000 claims description 16
- 108010065152 Coagulase Proteins 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 10
- 241000191940 Staphylococcus Species 0.000 claims description 8
- 239000013060 biological fluid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000219094 Vitaceae Species 0.000 claims description 3
- 235000021021 grapes Nutrition 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- 101710160102 Outer membrane protein B Proteins 0.000 claims 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 abstract description 46
- 238000010171 animal model Methods 0.000 abstract description 15
- 238000002955 isolation Methods 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 64
- 238000002360 preparation method Methods 0.000 description 63
- 241001465754 Metazoa Species 0.000 description 50
- 208000015181 infectious disease Diseases 0.000 description 39
- 230000001681 protective effect Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 29
- 229940008228 intravenous immunoglobulins Drugs 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 230000003053 immunization Effects 0.000 description 19
- 238000002649 immunization Methods 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 206010040047 Sepsis Diseases 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 15
- 208000031729 Bacteremia Diseases 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 241000282412 Homo Species 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 210000000440 neutrophil Anatomy 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 231100000518 lethal Toxicity 0.000 description 11
- 230000001665 lethal effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 229960003444 immunosuppressant agent Drugs 0.000 description 10
- 239000003018 immunosuppressive agent Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102400000368 Surface protein Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229920000136 polysorbate Polymers 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 6
- 108010044091 Globulins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000002960 lipid emulsion Substances 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000001861 immunosuppressant effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108700022034 Opsonin Proteins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940030156 cell vaccine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 244000052637 human pathogen Species 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 206010014665 endocarditis Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000004452 microanalysis Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 235000016236 parenteral nutrition Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000255930 Chironomidae Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 238000012511 carbohydrate analysis Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000625 opsonophagocytic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- DDSDPQHQLNAGLJ-YEBWQKSTSA-N (2z)-6-(2-chlorophenyl)-2-[(4-methylpiperazin-4-ium-1-yl)methylidene]-8-nitro-4h-imidazo[1,2-a][1,4]benzodiazepin-1-one;methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 DDSDPQHQLNAGLJ-YEBWQKSTSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000417321 Daemonorops aurea Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
- 241000191978 Staphylococcus simulans Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009177 immunoglobulin therapy Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ブドウ球菌に対して広範な反応性を有する抗体を誘導する、単離されたコアグ ラーゼ陰性ブドウ球菌の表面蛋白質。 2.抗体がスタフィロコッカス・エピダーミジス(Staphylococcus epidermidis) の三つの血清型すべてに対して広範な反応性を有する、請求項1に記載の蛋白質 。 3.スタフィロコッカス・エピダーミジス由来である、請求項1に記載の蛋白質。 4.約45,000〜50,000ダルトンの分子量を有し、約pH4.5の等電点を有する、請求 項3に記載の蛋白質。 5.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項3又は4に記載の蛋白質。 6.コアグラーゼ陰性ブドウ球菌の表面蛋白質に対する単離されたオプソニン作用 性抗体であって、該蛋白質がブドウ球菌に対して広範な反応性を有する抗体を誘 導するものである、抗体。 7.モノクローナル抗体又はポリクローナル抗体である、請求項6に記載の抗体。 8.スタフィロコッカス・エピダーミジスの三つの血清型すべてに対して広範な反 応性を有する、請求項6に記載の抗体。 9.蛋白質がスタフイロコッカス・エピダーミジス由来である、請求項6に記載の 抗体。 10.蛋白質が約45,000〜50,000ダルトンの分子量を有し、約pH4.5の等電点を有す るものである、請求項9に記載の抗体。 11.スタフィロコッカス・エピダーミジスが受託番号55133がでA.T.C.C.に寄託さ れた菌株Hayである、請求項9又は10に記載の抗体。 12.(a)免疫グロブリンの試料を準備する段階、 (b)ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラーゼ 陰性ブドウ球菌の表面蛋白質に対する抗体の存在について該免疫グロブリンを検 定する段階、及び (c)該抗体の高い力価を有する免疫グロブリンを単離する段階、 を含む、ブドウ球菌感染の治療及び予防に有効である広範な反応性を有するオプ ソニン作用性免疫グロブリンを単離する方法であって、該蛋白質に対する抗体の 存在がブドウ球菌感染の治療及び予防のための生物体液の有用性の指標となる、 方法。 13.蛋白質がスタフィロコッカス・エピダーミジス由来である、請求項12に記載 の方法。 14.蛋白質が約45,000〜50,000ダルトンの分子量であり、約pH4.5の等電点を有す る、請求項13に記載の方法。 15.蛋白質が受託番号55133でA.T.C.C.に寄託されたスタフィロコッカス・エピダ ーミジス菌株Hay由来である、請求項13又は14に記載の方法。 16.免疫グロブリンがポリクローナル抗体又はモノクローナル抗体を含む、請求 項12に記載の方法。 17.検定が結合性検定、オプソニン化検定、及びクリアランス検定からなる群よ り選択されるものである、請求項12に記載の方法。 18.該オプソニン化検定が細胞仲介型殺菌作用検定である請求項17に記載の方法 。 19.(a)ブドウ球菌に対して広範な反応性を有する、コアグラーゼ陰性ブドウ 球菌由来の表面蛋白質に対するオプソニン作用性抗体、及び (b)薬学的に許容される担体、 を含む、ブドウ球菌感染の治療又は予防のための薬学的組成物。 20.蛋白質がスタフィロコッカス・エピダーミジス由来である、請求項19に記載 の組成物。 21.蛋白質が約45,000〜50,000ダルトンの分子量を有し、約pH4.5の等電点を有す る、請求項20に記載の組成物。 22.蛋白質が受託番号55133でA.T.C.C.に寄託されたスタフィロコッカス・エピダ ーミジス菌株Hay由来である、請求項20又は21に記載の組成物。 23.薬学的に許容される担体が水、油、生理食生理食塩水溶液、水性デキストロ ース、及びグリセロール溶液からなる群より選択されるものである、請求項19に 記載の組成物。 24.(a)ブドウ球菌に対して広範な反応性を有する抗体を誘導する、治療に有 効な量のコアグラーゼ陰性ブドウ球菌由来の表面蛋白質、及び (b)薬学的に許容される担体、 を含む、ブドウ球菌感染の治療又は予防のためのワクチン。 25.蛋白質がスタフィロコッカス・エピダーミジス由来である、請求項24に記載 のワクチン。 26.蛋白質が約45,000〜50,000ダルトンの分子量を有し、約pH4.5の等電点を有す るものである、請求項25に記載のワクチン。 27.蛋白質が受託番号55133でA.T.C.C.に寄託されたスタフィロコッカス・エピダ ーミジス菌株Hay由来である、請求項25又は26に記載のワクチン。 28.薬学的に許容される担体が水、油、生理食生理食塩水溶液、水性デキストロ ース、及びグリセロール溶液からなる群より選択されるものである、請求項24に 記載の組成物。 29.蛋白質が第二化合物に複合化されている、請求項24に記載のワクチン。 30.第二化合物がS.アウレウス(S.aureus)血清型5、S.アウレウス血清型8、 又はS.エピダーミジスの莢膜多糖類である、請求項29に記載のワクチン。 31.第二化合物がグラム陰性微生物の莢膜多糖類である、請求項29に記載のワク チン。 32.ブドウ球菌に対して広範な反応性を有する抗体を誘導する、コアグラーゼ陰 性ブドウ球菌の血清型II莢膜多糖類抗原。 33.コアグラーゼ陰性グラム球菌に対して広範な反応性を有する抗体を誘導する 、請求項32に記載の抗原。 34.病原性のブドウ球菌に対して広範な反応性を有する抗体を誘導する、請求項3 2に記載の抗原。 35.スタフィロコッカス・エピダーミジス由来である、請求項32に記載の抗原。 36.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項35に記載の抗原。 37.コアグラーゼ陰性ブドウ球菌の血清型II莢膜多糖類抗原に対する単離された 抗体であって、該抗原がブドウ球菌に対して広範な反応性を有する抗体を誘導す るものである、抗体。 38.モノクローナル抗体又はポリクローナル抗体である、請求項37に記載の抗体 。 39.抗原がスタフィロコッカス・エピダーミジス由来である、請求項37に記載の 抗 体。 40.スタフイロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項39に記載の抗体。 41.(a)免疫グロブリンの試料を準備する段階、 (b)ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラーゼ 陰性ブドウ球菌の血清型II莢膜多糖類抗原に対する抗体の存在について該免疫グ ロブリンを検定する段階、及び (c)該抗体の高い力価を有する免疫グロブリンを単離する段階、 を含む、ブドウ球菌感染の治療及び予防に有効である広範な反応性を有するオプ ソニン作用性免疫グロブリンを単離する方法であって、該抗原に対する抗体の存 在がブドウ球菌感染の治療及び予防のための生物体液の有用性の指標となる、方 法。 42.抗原がスタフィロコッカス・エピダーミジス由来である、請求項41に記載の 方法。 43.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項42に記載の方法。 44.(a)ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラー ゼ陰性ブドウ球菌由来の血清型II莢膜多糖類抗原に対するオプソニン作用性抗体 、及び (b)薬学的に許容される担体、 を含む、ブドウ球菌感染の治療又は予防のための薬学的組成物。 45.抗原がスタフィロコッカス・エピダーミジス由来である、請求項44に記載の 組成物。 46.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項45に記載の組成物。 47.(a)ブドウ球菌に対して広範な反応性を有する抗体を誘導する、治療に有 効な量のコアグラーゼ陰性ブドウ球菌由来の血清型II莢膜多糖類抗原、及び (b)薬学的に許容される担体、 を含む、ブドウ球菌感染の治療又は予防に有効なワクチン。 48.抗原がスタフィロコッカス・エピダーミジス由来である、請求項47に記載の ワクチン。 49.抗原が受託番号55133でA.T.C.C.に寄託されたスタフィロコッカス・エピダー ミジス菌株Hay由来である、請求項48に記載のワクチン。 50.ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラーゼ陰性 ブドウ球菌由来の表面蛋白質に複合化された、請求項47に記載のワクチン。 51.表面蛋白質が約45,000〜50,000ダルトンの分子量を有し、約pH4.5の等電点を 有するものである、請求項50に記載のワクチン。 52.多糖類及び蛋白質が受託番号55133でA.T.C.C.に寄託されたスタフィロコッカ ス・エピダーミジス菌株Hay由来である、請求項50又は51に記載のワクチン。 53.(a)免疫グロブリンの試料を準備する段階、 (b)ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラーゼ 陰性ブドウ球菌の血清型II莢膜多糖類抗原に対する抗体の存在について該免疫グ ロブリンを検定する段階、 (c)ブドウ球菌に対して広範な反応性を有する抗体を誘導するコアグラーゼ 陰性ブドウ球菌の表面蛋白質抗原に対する抗体の存在について該免疫グロブリン を検定する段階、及び (d)該抗体の高い力価を有する免疫グロブリンを単離する段階、 を含む、ブドウ球菌感染の治療及び予防に有効である広範な反応性を有するオプ ソニン作用性免疫グロブリンを単離する方法であって、該抗原に対する抗体の存 在がブドウ球菌感染の治療及び予防のための生物体液の有用性の指標となる、方 法。 54.抗原がスタフィロコッカス・エピダーミジス由来である、請求項53に記載の 方法。 55.蛋白質抗原が、スタフィロコッカス・エピダーミジス由来であり、約45,000 〜50,000ダルトンの分子量を有し、約pH4.5の等電点を有するものである、請求 項53に記載の方法。 56.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項54又は55に記載の方法。 57.(a)免疫グロブリンの試料を提供する段階、 (b)ブドウ球菌に対して広範な反応性を有するオプソニン作用性抗体を誘導 する表面蛋白質抗原、莢膜多糖類抗原、又はそれらの組合せを有する血清型IIコ アグラーゼ陰性ブドウ球菌に対する抗体の存在について該免疫グロブリンを検定 する段階、及び (c)該抗体の高い力価を有する免疫グロブリンを単離する段階、 を含む、ブドウ球菌感染の治療及び予防に有効である広範な反応性を有するオプ ソニン作用性の免疫グロブリンを単離する方法であって、該プドウ球菌に対する 抗体の存在がブドウ球菌感染の治療及び予防のための生物体液の有用性の指標と なる、方法。 58.ブドウ球菌がスタフィロコッカス・エピダーミジスである、請求項57に記載 の方法。 59.スタフィロコッカス・エピダーミジスが受託番号55133でA.T.C.C.に寄託され た菌株Hayである、請求項58に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30849594A | 1994-09-21 | 1994-09-21 | |
US08/308,495 | 1994-09-21 | ||
PCT/US1995/011992 WO1996009321A1 (en) | 1994-09-21 | 1995-09-21 | Broadly reactive opsonic antibodies reactive with common staphylococcal antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000509961A true JP2000509961A (ja) | 2000-08-08 |
JP4160633B2 JP4160633B2 (ja) | 2008-10-01 |
Family
ID=23194201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51106696A Expired - Fee Related JP4160633B2 (ja) | 1994-09-21 | 1995-09-21 | 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0783520B1 (ja) |
JP (1) | JP4160633B2 (ja) |
AT (1) | ATE209659T1 (ja) |
AU (1) | AU707298B2 (ja) |
CA (1) | CA2200691C (ja) |
DE (1) | DE69524242T2 (ja) |
DK (1) | DK0783520T3 (ja) |
ES (1) | ES2169153T3 (ja) |
PT (1) | PT783520E (ja) |
WO (1) | WO1996009321A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008517918A (ja) * | 2004-10-21 | 2008-05-29 | ワイス | Staphylococcusepidermidisポリペプチド抗原の免疫原性組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
IT1298539B1 (it) | 1998-02-03 | 2000-01-12 | Bracco Spa | Metodo per la determinazione di infezioni da protesi |
US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
CN107096020A (zh) | 2009-06-22 | 2017-08-29 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的免疫原性组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233012T2 (de) * | 1991-11-22 | 2003-11-06 | Fattom, Ali Ibrahim | Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i |
EP1033135A1 (en) * | 1992-03-19 | 2000-09-06 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Broadly reactive opsonic antibodies that react with common staphyloccoccal antigens |
-
1995
- 1995-09-21 DK DK95933880T patent/DK0783520T3/da active
- 1995-09-21 AU AU36371/95A patent/AU707298B2/en not_active Ceased
- 1995-09-21 WO PCT/US1995/011992 patent/WO1996009321A1/en active IP Right Grant
- 1995-09-21 AT AT95933880T patent/ATE209659T1/de active
- 1995-09-21 PT PT95933880T patent/PT783520E/pt unknown
- 1995-09-21 CA CA2200691A patent/CA2200691C/en not_active Expired - Fee Related
- 1995-09-21 JP JP51106696A patent/JP4160633B2/ja not_active Expired - Fee Related
- 1995-09-21 DE DE69524242T patent/DE69524242T2/de not_active Expired - Lifetime
- 1995-09-21 EP EP95933880A patent/EP0783520B1/en not_active Revoked
- 1995-09-21 ES ES95933880T patent/ES2169153T3/es not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008517918A (ja) * | 2004-10-21 | 2008-05-29 | ワイス | Staphylococcusepidermidisポリペプチド抗原の免疫原性組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE69524242T2 (de) | 2002-05-23 |
EP0783520B1 (en) | 2001-11-28 |
DK0783520T3 (da) | 2002-03-25 |
ATE209659T1 (de) | 2001-12-15 |
PT783520E (pt) | 2002-05-31 |
DE69524242D1 (de) | 2002-01-10 |
CA2200691C (en) | 2011-02-15 |
EP0783520A1 (en) | 1997-07-16 |
WO1996009321A1 (en) | 1996-03-28 |
ES2169153T3 (es) | 2002-07-01 |
JP4160633B2 (ja) | 2008-10-01 |
AU707298B2 (en) | 1999-07-08 |
AU3637195A (en) | 1996-04-09 |
CA2200691A1 (en) | 1996-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5571511A (en) | Broadly reactive opsonic antibodies that react with common staphylococcal antigens | |
US20080139789A1 (en) | Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection | |
JP4353974B2 (ja) | 通常のスタフィロコーカス抗原と反応する広い反応性のオプソニン抗体 | |
US6692739B1 (en) | Staphylococcal immunotherapeutics via donor selection and donor stimulation | |
JP2009227680A (ja) | 腸球菌抗原およびワクチン | |
AU5696699A (en) | Staphylococcal immunotherapeutics via donor selection and donor stimulation | |
US7279162B1 (en) | Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection | |
EP0582672A1 (en) | Methods to detect and treat diseases caused by bacterial allergens | |
EP0628056A1 (en) | Directed human immune globulin for the prevention and treatment of staphylococcal infections | |
JP4160633B2 (ja) | 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体 | |
JP2565303B2 (ja) | 緑膿菌感染症の予防治療剤 | |
WO1996009321A9 (en) | Broadly reactive opsonic antibodies reactive with common staphylococcal antigens | |
Lee et al. | Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins | |
Okada et al. | Possible role for a polysaccharide antigen shared between Streptococcus pyogenes and S. mutans in the pathogenesis of poststreptococcal glomerulonephritis | |
AU667040C (en) | Methods to detect and treat diseases caused by bacterial allergens | |
JPH06339391A (ja) | シュウドモナス・エルギノサ感染の治療及び診断用抗体 | |
JPH0834798A (ja) | 新規なエシェリキア・コリ菌株から単離した1型およびp型フィムブリエ−アドヘシン、その製法ならびにその使用 | |
JPS62502284A (ja) | 抗原的に活性な蛋白質及び淋病の診断におけるその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050715 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071030 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080324 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080430 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080624 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080718 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110725 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120725 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120725 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130725 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |